Circulating cell-free DNA in patients with alveolar echinococcosis

Affiliation auteurs!!!! Error affiliation !!!!
TitreCirculating cell-free DNA in patients with alveolar echinococcosis
Type de publicationJournal Article
Year of Publication2018
AuteursBaraquin A, Hervouet E, Richou C, Flori P, Peixoto P, Azizi A, Delabrousse E, Blagosklonov O, Umhang G, Bresson-Hadni S, Valot B, Grenouillet F, Felix S, Heyd B, Mantion G, Di Martino V, Montange D, Vanlemmens C, Vuitton DAngele, Weil-Verhoeven D, Chavanet P, Dalle F, Gohier S, Minello A, Piroth L, Dumortier J, Mabrut J-Y, Wallon M, Frentiu E, Machouart M, Watelet J, Chemla C, Feron T, Heurge-Berlot A, Sommacale D, Thiefin G, Abou-Bacar A, Brunet J, Candolfi E, Hansmann Y, Lefebvre N, Grp EVStudy
JournalMOLECULAR AND BIOCHEMICAL PARASITOLOGY
Volume222
Pagination14-20
Date PublishedJUN
Type of ArticleArticle
ISSN0166-6851
Mots-clésAlveolar echinococcosis, biomarker, Circulating cell-free DNA, Digital PCR
Résumé

Alveolar echinococcosis (AE) is a parasitic disease, due to Echinococcus multilocularis. Often compared to liver cancer, it develops by infiltration from its primary site to the surrounding tissue, and can then metastasize to other organs. Detection of circulating cell-free DNA (ccfDNA) is a useful analytical tool in oncology, for diagnosis, prognosis, and therapy monitoring. This study sought to investigate the presence of ccfDNA in patients with AE, and its potential usefulness for the evaluation of treatment efficiency. To achieve these aims, a quantitative PCR and a droplet digital PCR were developed to detect E. multilocularis ccfDNA. An AE animal model identified, for the first time, the presence of large quantities of ccfDNA. Samples from patients with AE (n = 31) were then analyzed twice, at diagnosis, and after three months of chemotherapy: about 25% were positive, almost always with very low concentrations of ccfDNA. These results confirmed that E. multilocularis produces ccfDNA, as solid tumors do, but detection may not yet be sufficient for AE diagnosis nor for the evaluation of treatment efficiency, due to the low levels of ccfDNA detected in patient serum.

DOI10.1016/j.molbiopara.2018.04.004